Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$2.44 USD
-0.07 (-2.79%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $2.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EDIT 2.44 -0.07(-2.79%)
Will EDIT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EDIT
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Other News for EDIT
Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible
Editas Medicine Reaches Analyst Target Price
Editas Medicine (EDIT) Strengthens Despite FDA Division Shakeup
Gene editors steady despite latest leadership shake-up at FDA
JonesTrading Sticks to Their Hold Rating for Editas Medicine (EDIT)